DexCom, Inc. (NASDAQ:DXCM) Shares Sold by WoodTrust Financial Corp

WoodTrust Financial Corp trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,810 shares of the medical device company’s stock after selling 1,750 shares during the period. WoodTrust Financial Corp’s holdings in DexCom were worth $724,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. AlphaCentric Advisors LLC acquired a new position in DexCom during the 3rd quarter valued at about $280,000. Quintet Private Bank Europe S.A. boosted its holdings in shares of DexCom by 324.1% in the third quarter. Quintet Private Bank Europe S.A. now owns 4,105 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 3,137 shares in the last quarter. QRG Capital Management Inc. increased its stake in shares of DexCom by 8.6% during the third quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company’s stock valued at $1,052,000 after acquiring an additional 1,248 shares during the period. Asset Management One Co. Ltd. raised its holdings in DexCom by 10.4% during the third quarter. Asset Management One Co. Ltd. now owns 235,474 shares of the medical device company’s stock worth $15,786,000 after purchasing an additional 22,268 shares in the last quarter. Finally, National Pension Service lifted its position in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research analyst reports. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. UBS Group reduced their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Wells Fargo & Company boosted their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Price Performance

Shares of DXCM opened at $68.61 on Thursday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market capitalization of $26.80 billion, a price-to-earnings ratio of 41.08, a P/E/G ratio of 2.14 and a beta of 1.17. The business’s 50-day moving average is $69.66 and its 200-day moving average is $94.30. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.